Your browser doesn't support javascript.
loading
Molecularly Tailored Interface for Long-Term Xenogeneic Cell Transplantation.
Perikamana, Sajeesh Kumar Madhurakkat; Seale, Nailah; Hoque, Jiaul; Ryu, Ji Hyun; Kumar, Vardhman; Shih, Yuru Vernon; Varghese, Shyni.
Afiliação
  • Perikamana SKM; Department of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
  • Seale N; Department of Bioengineering University of California-San Diego La Jolla, CA 92093, USA.
  • Hoque J; Department of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
  • Ryu JH; Department of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
  • Kumar V; Department of Biomedical Engineering Duke University Durham, NC 27710, USA.
  • Shih YV; Department of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
  • Varghese S; Department of Orthopaedic Surgery Duke University School of Medicine Durham, NC 27710, USA.
Adv Funct Mater ; 32(4)2022 Jan 19.
Article em En | MEDLINE | ID: mdl-37920452
ABSTRACT
Encapsulation of therapeutic cells in a semipermeable device can mitigate the need for systemic immune suppression following cell transplantation by providing local immunoprotection while being permeable to nutrients, oxygen, and different cell-secreted biomolecules. However, fibrotic tissue deposition around the device has been shown to compromise the long-term function of the transplanted cells. Herein, a macroencapsulation device design that improves long-term survival and function of the transplanted cells is reported. The device is comprised of a semipermeable chitosan pouch with a tunable reservoir and molecularly engineered interface. The chitosan pouch interface decorated with 1,12-dodecanedioic acid (DDA), limits the cell adhesion and vigorous foreign body response while maintaining the barrier properties amenable to cell encapsulation. The device provides long-term protection to the encapsulated human primary hepatocytes in the subcutaneous space of immunocompetent mice. The device supports the encapsulated cells for up to 6 months as evident from cell viability and presence of human specific albumin in circulation. Solutions that integrate biomaterials and interfacial engineering such as the one described here may advance development of easy-to manufacture and retrievable devices for the transplantation of therapeutic cells in the absence of immunosuppression.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article